PhRMA Sues To Block 'Unprecedented' California Price Reporting Law
Executive Summary
Ban on WAC price increases violates Commerce Clause and reporting requirement violates First Amendment, PhRMA contends; complaint says state officials have not clarified whether law is retroactive.
You may also be interested in...
Mallinckrodt Must Publicize Price Increases In Wake Of DOJ Settlement On Medicaid Rebates
Under corporate integrity agreement, Mallinckrodt must post proposed list price increases for Acthar and other non-generic products along with a link to executive compensation. $234m settlement resolves allegations it underpaid Medicaid rebates resulting from Acthar price hikes.
Minnesota's Free Insulin Law Has 'Staggering' Implications, PhRMA Says
PhRMA sues to block implementation of the law, saying it could allow states to compel manufacturers to dispense other medications without compensation.
States Take Center Stage In Tackling Rx Drug Pricing
Dozen drug pricing transparency bills enacted into law over past two years impose different requirements on manufacturers, with a few honing in on PBMs; interactive graphic details these and other pharma-related laws.